Literature DB >> 16962758

Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD.

Osamu Nishiyama1, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Keisuke Kato, Tomoya Ogawa, Fumiko Watanabe, Shinichi Arizono.   

Abstract

The characteristics of dyspnoea in idiopathic pulmonary fibrosis (IPF) during a 6-min walk test are not clear. This study was designed to evaluate dyspnoea and desaturation during the 6-min walk test in IPF in comparison with that in chronic obstructive pulmonary disease (COPD), which is one of the most studied chronic lung diseases. The 41 consecutive patients with IPF included in this study were assessed by a 6-min walk test and concurrent measures of disease severity. Forty-one age-matched and resting PaO(2) value-matched COPD patients who had undertaken the test during the same period were selected as the control. Only O(2) saturation at the end of the test was an independent predictor of dyspnoea in IPF (r(2)=0.27, P=0.0005), whereas forced expiratory volume in 1s (FEV(1)) was the only predictor in COPD (r(2)=0.16, P=0.0096). Desaturation was significantly more severe in IPF (83.6+/-9.1% in IPF versus 88.0+/-5.9% in COPD, P<0.001). In contrast, dyspnoea assessed with the Borg scale was significantly more severe in COPD (3.6+/-2.1 in IPF versus 4.6+/-1.9 in COPD, P<0.05). O(2) saturation is an independent predictor of dyspnoea at the end of a 6-min walk test in IPF. In comparison with COPD, desaturation is more severe, although dyspnoea is milder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962758     DOI: 10.1016/j.rmed.2006.06.030

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Authors:  Jeffrey J Swigris; Frederick S Wamboldt; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Kevin K Brown
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

2.  Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Diane L Fairclough; Marianne Morrison; Barry Make; Elizabeth Kozora; Kevin K Brown; Frederick S Wamboldt
Journal:  Respir Care       Date:  2011-02-11       Impact factor: 2.258

3.  MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study.

Authors:  Effrosyni D Manali; Panagiotis Lyberopoulos; Christina Triantafillidou; Likourgos F Kolilekas; Christina Sotiropoulou; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  BMC Pulm Med       Date:  2010-05-28       Impact factor: 3.317

4.  Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users.

Authors:  Mengshu Cao; Frederick S Wamboldt; Kevin K Brown; Jonathon Hickman; Amy L Olson; Joshua J Solomon; Jeffrey J Swigris
Journal:  Multidiscip Respir Med       Date:  2015-11-30

Review 5.  Opioids: an unexplored option for treatment of dyspnea in IPF.

Authors:  Charlotte Kohberg; Charlotte Uggerhøj Andersen; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2016-03-10

6.  Daily physical activity affects exercise capacity in patients with idiopathic pulmonary fibrosis.

Authors:  Akira Morino; Hiroki Takahashi; Hirofumi Chiba; Sumio Ishiai
Journal:  J Phys Ther Sci       Date:  2017-08-10

7.  Factors affecting dyspnea after the 6-minute walk test in idiopathic pulmonary fibrosis patients presenting with exercise-induced hypoxemia.

Authors:  Akira Morino; Hiroki Takahashi; Hirofumi Chiba; Sumio Ishiai
Journal:  J Phys Ther Sci       Date:  2017-08-10

8.  Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Can Respir J       Date:  2016-05-18       Impact factor: 2.409

9.  Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.

Authors:  Xin Geng; Kobina Dufu; Athiwat Hutchaleelaha; Qing Xu; Zhe Li; Chien-Ming Li; Mira P Patel; Nicholas Vlahakis; Josh Lehrer-Graiwer; Donna Oksenberg
Journal:  Physiol Rep       Date:  2016-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.